BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DS-2243a readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of DS-2243a\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06644755-2462@assetmemo.bio
DTSTAMP:20261121T005433Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:DS-2243a: Phase 1 readout est. (NCT06644755)
DESCRIPTION:DS-2243a\, phase 1.\nStudy: First-in-Human Trial of DS-2243a in
  Participants With Advanced Solid Tumors\nEstimated primary completion: 30
  November 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ds-22
 43a#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06644755
URL:https://assetmemo.bio/drug/ds-2243a#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
